23 results about "Glucose uptake" patented technology

The invention discloses hippophae rhamnoides polysaccharide with the activity of reducing blood sugar and blood fat as well as a preparation method and application thereof. Adding water into the degreased hippophae rhamnoides, adjusting the pH value to be acidic, then heating, stirring and extracting under an ultrasonic condition, and collecting filtrate; and performing post-treatment to obtain the sea-buckthorn polysaccharide. The content of neutral sugar in the sea buckthorn polysaccharide is 25.31%-30.68%, the content of uronic acid in the sea buckthorn polysaccharide is 54.66%-59.79%, and the content of protein in the sea buckthorn polysaccharide is 1.91%-2.14%. According to the method, the sea-buckthorn polysaccharide is extracted by adopting acid assistance-ultrasonic extraction, and the prepared sea-buckthorn polysaccharide has remarkable blood sugar and blood fat reducing activity. When the concentration of the sea-buckthorn polysaccharide is as low as 0.1 mg / mL, the glucose uptake of HepG2-IR cells can still be obviously improved, and the content of total cholesterol and total triglyceride of the HepG2-IR cells can be obviously reduced. The hippophae rhamnoides polysaccharide can be applied to preparation of food or medicine for reducing blood sugar and / or blood fat.

The invention relates to a hyaluronic acid high-yield strain based on metabolic flow optimization as well as a construction method and application thereof, and belongs to the technical field of genetic engineering. According to the corynebacterium glutamicum, sources of key rate-limiting enzymes UDP-glucose dehydrogenase and glutamine-fructose-6-phosphate aminotransferase are screened, and heterologous expression of hyaluronic acid synthase and overexpression of endogenous inositol permease and glucokinase are combined, so that the corynebacterium glutamicum capable of highly producing hyaluronic acid is constructed in a form of optimizing metabolic flux; according to the invention, the hyaluronic acid is used as a substrate, polyhydroxybutyrate synthase clusters are further overexpressed in the substrate, the glucose uptake and utilization efficiency of a host are improved, the metabolic coupling of cofactors is realized, the yield of the hyaluronic acid reaches 45g / L, the production intensity is 1.25 g / L / h, a brand new tool is provided for the production of the hyaluronic acid, and the method has an excellent application prospect.

An agent is for inhibiting glucose uptake into red blood cells and a blood collection tube suppresses glucose concentration decrease. The agent for inhibiting glucose uptake into red blood cells includes inosine as an active ingredient. The inhibition agent can be used for suppressing a decrease in glucose concentration of whole blood collected in a blood collection tube. The blood collection tube includes inosine in an internal space. The blood collection tube can be used to measure glucose concentration in blood. The blood collection tube can further include a glycolysis inhibitor.

The invention discloses a compound polysaccharide preparation for treating diabetes and application thereof, and belongs to the technical field of biomedicine. The compound polysaccharide preparation is composed of compound polysaccharide A and compound polysaccharide B according to the mass ratio of 1: 1. The compound polysaccharide A is prepared from abelmoschus esculentus and chlorella through alkaline ultrasonic extraction and 10-100kDa ultrafiltration classification; the compound polysaccharide B is prepared by performing enzymolysis and hot water extraction on grifola frondosa and sarcodon aspratus. Experiments prove that the preparation can significantly improve insulin secretion and glucose uptake ability of islet cells, effectively reduce fasting blood-glucose of type 2 diabetes model mice and synchronously improve triglyceride and total cholesterol levels through strong synergistic interaction among the components. The preparation disclosed by the invention is natural in source, safe and efficient, so that a new choice is provided for medicine development of type 2 diabetes mellitus.

The present application relates to the field of medical detection, in particular to a probe combination for full-spectrum flow cytometry detection of cell metabolism and application thereof. Traditional flow cytometry is limited by fluorescence channel overlap and cannot simultaneously detect multiple metabolic states in the same sample, affecting detection efficiency and data accuracy. The present application optimizes the probe combination and uses full-spectrum flow cytometry to achieve simultaneous detection of two or more metabolic probes, simultaneously detecting multiple metabolic indicators such as intracellular fatty acid uptake, glucose uptake, active oxygen level, and mitochondrial function, and ensuring the compatibility of fluorescence signals between probes. The method of the present application can reduce sample consumption and improve detection efficiency, and is suitable for metabolic analysis of trace clinical samples and rare cell populations, and is widely used in the fields of tumor research, metabolic disease monitoring, drug screening, etc., and provides an efficient and accurate technical means for single-cell level metabolic research.

This invention relates to peptide complexes with anti-diabetic activity and their uses. The peptide complexes of this invention promote cellular glucose uptake, inhibit insulin resistance signaling, promote insulin sensitivity signaling, and inhibit apoptosis of pancreatic β-cells, which are insulin-producing cells, thereby exhibiting a blood glucose-lowering effect. Furthermore, this invention also relates to peptides with anti-diabetic and anti-obesity activities and their uses. The peptides of this invention have activities that inhibit insulin resistance signaling, promote insulin sensitivity signaling, and promote lipolysis in adipocytes.

The invention discloses a nanoliter reactor responding to extracellular L-tryptophan concentration as well as a preparation method and application of the nanoliter reactor. The method comprises the following steps: firstly, transforming escherichia coli through metabolic engineering to construct a sensor strain, and knocking out glucose uptake related genes to form a carbon source orthogonality; l-tryptophan synthesis related genes are inactivated, so that the growth of the L-tryptophan completely depends on exogenous L-tryptophan; next, xylose is replaced by a biosensor element capable of responding to L-tryptophan by using a promoter of a gene, and then a constitutive expression fluorescent protein gene is inserted, so that positive correlation between fluorescence output of a sensor strain and the concentration of L-tryptophan is realized. The sensor bacteria and L-tryptophan producing bacteria are jointly encapsulated in sodium alginate gel microspheres to prepare a nano-liter-scale reactor, so that co-culture of the two strains in the same microenvironment is realized. The overall fluorescence intensity of the microspheres can visually reflect the ability of producing bacteria to synthesize and release L-tryptophan.

This invention relates to the field of biomedical technology, specifically to the application of TXNIP gene expression inhibitors in the preparation of drugs for treating primary biliary cholangitis. This invention discovers the complete mechanism by which hepatocytes regulate glucose uptake through TXNIP, thereby influencing T cell metabolism and driving Th1 differentiation, thus exacerbating intrahepatic inflammation in primary biliary cholangitis (PBC). This clarifies TXNIP as a potential new target for intervening in the progression of PBC, and therefore proposes the application of TXNIP gene expression inhibitors in the preparation of drugs for treating PBC.

The present technology comprises pharmaceutical compositions of non-naturally occurring melanocortin analogs formulated for oral administration. The non-naturally occurring melanocortin analogs may be agonists or antagonists of the melanocortin 5 receptor (MC5R) with sub-micromolar or low-nanomolar binding activity. In some embodiments, the pharmaceutical compositions are formulated to deliver about 0.1 mg / kg to about 5 mg / kg, per body weight of a subject.

The invention provides gynura divaricata polysaccharide as well as a preparation method and application thereof, and belongs to the field of polysaccharide preparation. The homogeneous component GDP1 of the gynura divaricata polysaccharide is mainly prepared from fructose, glucose, arabinose and galactose according to the molar ratio of 58.4: 39.08: 0.75: 0.78; the molecular weight Mw is 6684Da, and the purity is 99.04%; t2DM mouse in-vivo hypoglycemic activity research is carried out, and the prepared gynura divaricata polysaccharide can relieve the symptom of weight loss of mice, relieve the hyperglycemia and insulin resistance level of the mice and regulate the abnormal conditions of the blood fat level, the oxidative stress level and the inflammation level of the mice. The PI3K / Akt / GLUT-4 signal channel is activated to increase the glucose uptake of the T2DM mouse and reduce the insulin resistance of the T2DM mouse, so that the blood glucose metabolism of the T2DM mouse is improved. The gynura divaricata polysaccharide can be used for preparing medicines for treating type 2 diabetes mellitus.

The present application discloses the use of SUR2 receptor modulators. In the present application, SUR2 receptor modulators (e.g. MLC1) can be combined with skeletal muscle cell K ATP SUR2 specific binding on potassium ion channel, thus enhancing intracellular calcium signal, increasing glucose uptake of skeletal muscle cell and reducing blood glucose, and thus can be used as a therapeutic drug for diabetes; SUR2 receptor modulators selectively bind to SUR2 through a non-islet β cell dependent mechanism, and have no inhibitory effect on islet β cell SUR1 receptor, and thus can effectively avoid hypoglycemia while reducing blood glucose, and have small side effects.

The invention discloses dendrobium officinale oligosaccharide as well as a preparation method and application thereof, and belongs to the technical field of preparation of functional components of natural products. According to the invention, by optimizing the process conditions of enzymolysis of dendrobium officinale polysaccharide by beta-mannase, including substrate concentration, enzyme dosage, pH, temperature and time, and purifying, the dendrobium officinale oligosaccharide (DOO1) with the molecular weight of about 921 Da, the molar ratio of mannose to glucose of about 4.53: 1 and the main glucosidic bond of-> 4)-beta-D-Manp-(1->) is obtained. According to the prepared dendrobium officinale oligosaccharide, the solubility and bioavailability of the dendrobium officinale oligosaccharide are remarkably improved, the good alpha-amylase inhibitory activity is shown, the effect of improving insulin to resist cell glucose uptake is achieved, and the functional application potential of dendrobium officinale is further expanded.

The invention relates to the technical field of medicine and chemistry, and particularly discloses an isopentenyl flavonoid compound derived from Morus nigra L. as well as a preparation method and application of the isopentenyl flavonoid compound. The isopentenyl flavonoid compound can remarkably promote glucose uptake and effectively improve the glucose uptake capacity of insulin-resistant cells, so that the isopentenyl flavonoid compound has application potential in the aspect of preparing the medicine for treating diabetes mellitus and can be used for preparing the medicine for treating diabetes mellitus.

The present technology is directed to managing blood glucose levels in patients and associated systems and methods. For example, the present technology provides a method for decreasing blood glucose levels in patients by delivering electrical signals to a spinal column of the patient via an implanted signal delivery device. The stimulation induces motor contractions in the lower extremity or abdomen, thus causing glucose uptake from the bloodstream in an insulin-independent manner.

This invention relates to the biomedical field, specifically to interventional peptides for preparing drugs to treat diabetes, comprising: (a) SEQ ID No. 1; (b) a fusion protein formed by peptide (a) and a transmembrane peptide element; and (c) a peptide derivative of peptide (a) or (b) by deletion, insertion, or substitution of one or more amino acids, and having the same biological function as the peptide molecule described in (a) or (b). This invention has undergone extensive screening and validation at the cellular level and in animal experiments, and has also been tested using serum samples from clinical patients, confirming that the peptides can specifically lower blood glucose levels, promote cellular glucose uptake, and promote glycogen synthesis, thereby improving diabetes symptoms; it only affects glucose metabolism, therefore has few side effects, a long half-life, and significant clinical implications.

The application discloses a preparation method of glucose oxidase / simvastatin magnetic nanomotor, and steps are as follows: FeCl3.6H2O is added into deionized water and stirred, sodium citrate, urea and PAM are added, and after stirring, reaction is carried out in a Teflon autoclave to obtain Fe3O4 nano solution; PAA and ammonia water are added and stirred, and then isopropyl alcohol is added dropwise to obtain Fe3O4-PAA nano solution; tetraethyl orthosilicate is added and stirred, and then washing is carried out to obtain Fe3O4-PAA / mSiO2 nano solution; simvastatin is mixed with the nano solution to obtain Sim-loaded Fe3O4-PAA / mSiO2 nanoparticles; EDC and NHS solution are added and stirred, and then glucose oxidase is added, and finally glucose oxidase-simvastatin magnetic nanomotor is obtained; the method utilizes the driving of the magnetic nanomotor in the magnetic field and the catalytic reaction of GOx, enhances the targeting and permeability of the drug in the tumor, and the loaded simvastatin can affect the lipid metabolism of tumor cells and inhibit glucose uptake, and compared with the use of GOx alone, the anti-tumor activity is significantly improved.

A method allows people to not compromise on the taste and flavor of sugar-containing foods and beverages, while reducing the net effect of the sugar in the body. The method may include oral consumption of the enzyme alternansucrase to convert up to 90% of consumed sucrose and other carbohydrates into a carbohydrate complex of undigestible or slowly digestible α-1, 3 and α-1, 6 glucan fibers in the gastrointestinal tract. These glucan fibers have the properties of dietary fibers and a degree of polymerization ranging from 3 to greater than 100. The methods may aid in glucose control, reduce insulin resistance and support healthy glucose homeostasis in diabetic and pre-diabetic conditions. It may promote healthy gut bacteria and improve bowel movements to benefit overall digestive health. It may also be applied to obesity control by reducing blood glucose and, through the production of fiber, blood lipid levels, which supports cardiovascular health.

The application discloses application of KIDINS220 in preparation of products for assisting in diagnosis of obesity or treatment of obesity, and belongs to the technical field of biological medicine. The application finds that hybrid mutation of KIDINS220 gene leads to reduction of protein expression of KIDINS220, and then reduces combination with AKT2, and causes reduction of phosphorylation level of AKT signal path; AKT2 is a core kinase of insulin signal in adipose tissue, and disorder of activation of AKT2 can cause reduction of glucose uptake, increase of lipid synthesis, and finally cause obesity. An agent for promoting interaction between KIDINS220 gene or protein and AKT2 and a polypeptide for specifically recognizing and combining KIDINS220 and AKT2 can be used for treatment of obesity. The treatment strategy has higher molecular specificity and safety, and is more suitable for large-scale application of overweight and mild to moderate obesity population.

The present technology comprises non-naturally occurring melanocortin analogs or pharmaceutically acceptable salts, solvates, or stereoisomers thereof and compositions comprising the same. The non-naturally occurring melanocortin analogs may selectively bind the melanocortin 3 receptor and / or the melanocortin 4 receptor over the melanocortin 1, melanocortin 2, and melanocortin 5 receptors. In some embodiments, the non-naturally occurring melanocortin analogs are antagonists of melanocortin 3 and / or 4 receptors with sub-micromolar or low-nanomolar binding activity.

The invention provides a construction method and application of a bacillus amyloliquefaciens chassis strain, bacillus amyloliquefaciens HZ12 is taken as a starting strain, two key genes of a non-PTS system are screened and identified from a glucose transport pathway, and the bacillus amyloliquefaciens chassis strain is obtained. According to the present invention, the L-tyrosine genes are respectively a glucose osmose gene Bao-glcP1 derived from bacillus amyloliquefaciens and a glucokinase gene Cgb-glK derived from corynebacterium glutamicum, and after the genes are subjected to overexpression, the L-tyrosine yields of the engineering bacteria respectively achieve 395.82 mg / L and 385.37 mg / L, and are increased by 36% and 33% compared with the original strain; then, by strengthening a non-PTS system, weakening the PTS system and reconstructing glucose uptake and phosphorylation pathways of the strain, the phosphorylation process of glucose and PEP are decoupled, a chassis strain with high yield of L-tyrosine is obtained, and the yield of L-tyrosine is increased to 407.16 mg / L and is increased by 43% compared with that of an original strain. Key rate-limiting enzyme genes aroA and tyrA for synthesizing L-tyrosine are further overexpressed in the chassis strain, so that the yield of the L-tyrosine is increased to 1400.53 mg / L and is increased by 3.82 times compared with that of an original strain.

The invention discloses an I-type CRISPRi (clustered regularly interspaced short palindromic repeats i) system based on ComQXPA quorum sensing, an engineering bacterium and an application of the I-type CRISPRi system. According to the invention, a pantoic acid synthesis route is enhanced, cofactors and energy supply are optimized, precursor pyruvic acid accumulation and glucose uptake efficiency are improved, and high-yield D-pantothenic acid engineering chassis bacteria are constructed; and the bacillus subtilis endogenous QS-mediated I-type CRISPRi system is used for dynamic regulation and control of ccpA, odhA and ptsG genes to obtain the probiotic engineering bacteria capable of responding to the population density. The strain can dynamically regulate and balance intracellular metabolic flux through self-induction, intermediate product accumulation is avoided, efficient synthesis of D-pantothenic acid is achieved, the shake flask yield reaches 8.66 g / L, and the yield of a 5L bioreactor reaches 32.26 g / L.

A method of treating diabetes or a related complication in a subject in need thereof, the method comprising: administering a therapeutically effective amount of epithelial mitogen or a functional fragment thereof to the subject. The method can be used to lower the amount of circulating glucose in the subject by enhancing glucose uptake by hepatocytes and myocytes in an insulin-dependent and independent manner, and pancreatic beta cell regeneration.

A computer-implemented method for treating a patient suffering from Type I Diabetes (T1D). The method can include quantifying physical activity (PA) of the patient; calculating an accumulated PA periodically based on the quantified PA, the accumulated PA indicating an aggregate of the PA; and generating an activity informed insulin bolus by adjusting a prevalent functional insulin therapy bolus with a previous activity component, wherein the previous activity component is based on the accumulated daily PA, an activity profile, and an activity factor of the patient. The method can include determining an additional glucose uptake within a time period, the additional glucose uptake being caused by a PA; translating the additional glucose uptake into a number of insulin units with a same BG lowering impact; and generating an activity informed insulin bolus by adjusting a prevalent functional insulin therapy bolus with the insulin units.